Equities research analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to post $1.54 billion in sales for the current quarter, Zacks reports. Eight analysts have provided estimates for Regeneron Pharmaceuticals’ earnings. The highest sales estimate is $1.68 billion and the lowest is $1.44 billion. Regeneron Pharmaceuticals posted sales of $1.32 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 16.7%. The company is expected to report its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full-year sales of $1.54 billion for the current financial year, with estimates ranging from $6.08 billion to $6.94 billion. For the next financial year, analysts anticipate that the company will post sales of $7.14 billion per share, with estimates ranging from $6.56 billion to $7.92 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.18 by $1.05. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The business’s revenue for the quarter was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.04 EPS.
Several research firms have recently commented on REGN. BTIG Research reaffirmed a “buy” rating and set a $520.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. Canaccord Genuity lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the company from $522.00 to $356.00 in a research report on Wednesday. Cowen reaffirmed a “hold” rating and set a $450.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 7th. Robert W. Baird raised shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research report on Friday, February 9th. They noted that the move was a valuation call. Finally, Leerink Swann reduced their price target on shares of Regeneron Pharmaceuticals from $568.00 to $502.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Three investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $450.65.
Regeneron Pharmaceuticals (REGN) traded down $5.53 during mid-day trading on Friday, hitting $317.51. 926,615 shares of the stock traded hands, compared to its average volume of 1,072,069. The stock has a market cap of $34,200.00, a price-to-earnings ratio of 24.16, a PEG ratio of 1.04 and a beta of 1.47. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals has a 1 year low of $313.53 and a 1 year high of $543.55.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $325.60, for a total value of $325,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.80% of the company’s stock.
Large investors have recently bought and sold shares of the business. Shell Asset Management Co. grew its stake in shares of Regeneron Pharmaceuticals by 24.1% in the third quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock worth $5,565,000 after acquiring an additional 2,999 shares in the last quarter. DnB Asset Management AS acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $9,136,000. Northpointe Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $2,089,000. Cubist Systematic Strategies LLC grew its stake in shares of Regeneron Pharmaceuticals by 176.1% in the second quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock worth $330,000 after acquiring an additional 428 shares in the last quarter. Finally, Griffin Asset Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $1,579,000. Institutional investors and hedge funds own 64.67% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/02/21/regeneron-pharmaceuticals-inc-regn-expected-to-announce-quarterly-sales-of-1-54-billion.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.